Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.55 USD
Change Today -0.18 / -2.67%
Volume 58.6K
CCM On Other Exchanges
Symbol
Exchange
Berlin
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

concord medical - spon adr (CCM) Snapshot

Open
$6.70
Previous Close
$6.73
Day High
$6.71
Day Low
$6.50
52 Week High
07/23/14 - $8.47
52 Week Low
05/8/14 - $5.18
Market Cap
294.4M
Average Volume 10 Days
111.4K
EPS TTM
$0.38
Shares Outstanding
44.9M
EX-Date
08/5/14
P/E TM
17.3x
Dividend
--
Dividend Yield
13.74%
Current Stock Chart for CONCORD MEDICAL - SPON ADR (CCM)

concord medical - spon adr (CCM) Related Bloomberg News

View More Bloomberg News

concord medical - spon adr (CCM) Related Businessweek News

View More BusinessWeek News

concord medical - spon adr (CCM) Details

Concord Medical Services Holdings Limited, through its subsidiaries, operates radiotherapy and diagnostic imaging centers. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, CyberKnife robotic radiosurgery system, proton beam therapy, and diagnostic imaging services. The company also offers other treatments and diagnostic services through the use of medical equipment comprising electroencephalography for the diagnosis of epilepsy; thermotherapy for pain relief after radiotherapy and chemotherapy; ultrasound therapy for the treatment of cancer; stereotactic radiofrequency ablation for the treatment of Parkinson’s disease; and refraction and tonometry for the diagnosis of ophthalmic conditions. In addition, it provides clinical support services, such as developing treatment protocols for doctors; and organizing joint diagnosis between doctors in its network and clinical research. Further, the company offers radiotherapy and diagnostic equipment leasing and management services to hospitals, as well as is engaged in the sale of medical equipment. The company, through its subsidiaries, holds 52% equity interest in Chang’an Hospital, a non-public general hospital with 1,100 hospital beds located in Xi’an, Shaanxi Province. It also focuses on establishing the Beijing Proton Medical Center that would offer radiotherapy treatment options to cancer patients; and Guangzhou Concord Medical Cancer Hospital, a 400-bed specialty hospital for cancer diagnosis and treatment, as well as other specialty cancer hospitals that would offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of June 30, 2014, it operated a network of 141 centers with 81 hospitals in 56 cities, and 25 provinces and administrative regions in China. The company was founded in 1996 and is headquartered in Beijing, the People’s Republic of China.

Founded in 1996

concord medical - spon adr (CCM) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

concord medical - spon adr (CCM) Key Developments

Concord Medical Services Holdings Limited Presents at China Healthcare Investment Conference - Shanghai, Mar-31-2015 through Apr-02-2015

Concord Medical Services Holdings Limited Presents at China Healthcare Investment Conference - Shanghai, Mar-31-2015 through Apr-02-2015. Venue: Shangri-La Pudong Hotel, 33 Fu Cheng Road, Pudong, Shanghai 200120, China. Presentation Date & Speakers: Apr-01-2015, Adam Jigang Sun, Chief Investment Officer.

Concord Medical Services Holdings Limited Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; to Open Cancer Hospital in Datong

Concord Medical Services Holdings Limited reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total net revenues from the network business were RMB 160.3 million, an 8.3% decrease from RMB 174.8 million in the fourth quarter of 2013, primarily due to decreased treatment and diagnostic patient cases as a result of the closure of two centers due to contract expiration. Operating income was RMB 48.8 million for the fourth quarter of 2014, compared to RMB 53.3 million in the fourth quarter of 2013. Net income attributable to ordinary shareholders was RMB 28.1 million for the fourth quarter of 2014, compared to RMB 11.1 million in the fourth quarter of 2013. Non-GAAP net income for the fourth quarter of 2014 was RMB 33.1 million, compared to RMB 14.2 million for the fourth quarter of 2013. Both non-GAAP basic and diluted earnings per ADS in the fourth quarter of 2014 were RMB 0.74. Both basic and diluted earnings per ADS for the fourth quarter of 2014 were RMB 0.64. Adjusted EBITDA (non-GAAP) was RMB 101.7 million for the fourth quarter of 2014, representing a 14.0% increase from the fourth quarter of 2013. Income from continuing operations before income tax was RMB 47.504 million against RMB 42.755 million a year ago. Net income from continuing operations was RMB 6.708 million or RMB 0.15 per basic and diluted share against RMB 12.047 million or RMB 0.27 per basic and diluted share a year ago. Adjusted EBITDA was RMB 101.681 million against RMB 99.942 million a year ago. For the year, the company reported total net revenues in 2014 were RMB 606.9 million, representing a 7.8% increase from RMB 563.1 million in 2013, mainly due to the increased revenue contributions from diagnostic equipment patients. Operating income in 2014 was RMB 183.6 million, a 17.5% increase from RMB 156.3 million in 2013. Net income attributable to ordinary shareholders in 2014 was RMB 124.7 million, a 44.5% increase from RMB 86.3 million in 2013. Non-GAAP net income for the full year of 2014 was RMB 114.0 million, compared to RMB 95.3 million for the full year of 2013. Non-GAAP basic and diluted earnings per ADS in 2014 were RMB 2.54 and RMB 2.53, respectively. Basic and diluted earnings per ADS in 2014 were RMB 2.77 and RMB 2.76, respectively. Adjusted EBITDA (non-GAAP) was RMB 348.6 million in 2014, representing an 9.3% increase from RMB 318.9 million in 2013. Capital expenditures were RMB 107.8 million in 2014, compared to RMB 159.8 million in 2013. Income from continuing operations before income tax was RMB 175.646 million against RMB 144.269 million a year ago. Net income from continuing operations was RMB 94.796 million or RMB 2.10 per diluted share against RMB 80.431 million or RMB 1.79 per basic and diluted share a year ago. Adjusted EBITDA was RMB 348.638 million against RMB 318.889 million a year ago. The company expects to open first specialized cancer hospital in Datong in the first half of 2015. This will be a oncology facility once complete. The company also expects hospitals in Guangzhou and Shanghai to also break ground in 2015.

Concord Medical Services Holdings Limited to Report Q4, 2014 Results on Mar 23, 2015

Concord Medical Services Holdings Limited announced that they will report Q4, 2014 results at 5:00 PM, China Standard Time on Mar 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCM:US $6.55 USD -0.18

CCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Renji Medical Group Ltd/Hong Kong $0.34 HKD +0.015
View Industry Companies
 

Industry Analysis

CCM

Industry Average

Valuation CCM Industry Range
Price/Earnings 19.3x
Price/Sales 3.0x
Price/Book 1.0x
Price/Cash Flow 5.4x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONCORD MEDICAL - SPON ADR, please visit www.cmsholdings.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.